MTOR and renal cell carcinoma: In conclusion, evidence derived from six prospective and retrospective cohort studies substantiates the prognostic significance of IL-8 in advanced RCC, in terms of both OS and, to a lesser extent, PFS; such prognostic effect is particularly evident in cohorts of patients treated with either immunotherapy or mTOR inhibitors.